Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets

World Journal of Clinical Oncology

Volumn 5, Issue 3, 2014, Pages 335-347

  Rucci, Nadia ^a   Sanità, Patrizia ^a   Monache, Simona Delle ^a   Alesse, Edoardo ^a   Angelucci, Adriano ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Bone metastasis; Breast cancer; Osteoclasts; Targeted therapy

Indexed keywords

EID: 84916212617     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i3.335     Document Type: Review

References (119)

1. Viadana E, Bross ID, Pickren JW. An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer 1973; 27: 336-340 [PMID: 4701705]
2. Angelucci A, Edoardo Alesse M. Molecular Pathology of Cancer Metastasis: Suggestions for Future Therapy. Biotargets of Cancer in Current Clinical Practice: Springer, 2012: 469-515
3. Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6: 339-351 [PMID: 19399023 DOI: 10.1038/nrclinonc.2009.44]
4. Li S, Peng Y, Weinhandl ED, Blaes AH, Cetin K, Chia VM, Stryker S, Pinzone JJ, Acquavella JF, Arneson TJ. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol 2012; 4: 87-93 [PMID: 22570568 DOI: 10.2147/CLEP.S28339]
5. Koizumi M, Yoshimoto M, Kasumi F, Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003; 14: 1234-1240 [PMID: 12881385]
6. Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, McCart Reed AE, Kutasovic JR, Morey AL, Marquart L, ORourke P, Lakhani SR. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol 2014; 232: 23-31 [PMID: 24122263 DOI: 10.1002/path.4288]
7. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007; 110: 2640-7 [PMID: 17960791 DOI: 10.1002/cncr.23088]
8. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-66 [PMID: 3814476]
9. Kwai AH, Stomper PC, Kaplan WD. Clinical significance of isolated scintigraphic sternal lesions in patients with breast cancer. J Nucl Med 1988; 29: 324-328 [PMID: 3346742]
10. Roodman GD. Mechanisms of bone metastasis. Discov Med 2004; 4: 144-148 [PMID: 20704976]
11. Raisz LG, Sandberg AL, Goodson JM, Simmons HA, Mergenhagen SE. Complement-dependent stimulation of prostaglandin synthesis and bone resorption. Science 1974; 185: 789-791 [PMID: 4843377]
12. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89: 2031-2037 [PMID: 14647134 DOI: 10.1038/sj.bjc.66014376601437]
13. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101 [PMID: 2673568 DOI: 10.1016/S0140-6736(00)49915-0]
14. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874 [PMID: 11553815 DOI: 10.1073/pnas.19136709898/19/10869]
15. St Romain P, Madan R, Tawfik OW, Damjanov I, Fan F. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. Hum Pathol 2012; 43: 398-404 [PMID: 21840040 DOI: 10.1016/j.humpath.2011.05.009S0046-8177(11)00219-X]
16. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197-206 [PMID: 9916131 DOI: 10.1172/JCI3523]
17. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: A nationwide cohort study. Breast Cancer Res 2011; 13: R87 [PMID: 21914172 DOI: 10.1186/bcr2944]
18. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 7737-7742 [PMID: 12808139 DOI: 10.1073/pnas.13319311001331931100]
19. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986; 81: 381-386 [PMID: 2428242]
20. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9 Suppl 4: 14-27 [PMID: 15459426 DOI: 10.1634/theoncologist.9-90004-149/suppl-4/14]
21. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057 [PMID: 12963702 DOI: 10.1200/JCO.2003.08.017J CO.2003.08.017]
22. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9: 2643-2658 [PMID: 14529538]
23. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12: 6222s-6230s [PMID: 17062705]
24. Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005; 65: 4971-4974 [PMID: 15958534]
25. Bezzi M, Hasmim M, Bieler G, Dormond O, Röegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factorinduced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003; 278: 43603-43614 [PMID: 12933798 DOI: 10.1074/jbc.M308114200M308114200]
26. Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 1999; 79: 15-20 [PMID: 9928771]
27. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11: 4451-4459 [PMID: 15958630]
28. Del Fattore A, Teti A, Rucci N. Bone cells and the mechanisms of bone remodelling. Front Biosci (Elite Ed) 2012; 4: 2302-2321 [PMID: 22202038]
29. Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007; 13: 791-801 [PMID: 17618270]
30. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007; 170: 427-435 [PMID: 17255310]
31. Walker DG. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 1975; 190: 784-785 [PMID: 1105786]
32. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999; 190: 1741-1754 [PMID: 10601350]
33. Baron R, Neff L, Louvard D, Courtoy PJ. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 1985; 101: 2210-2222 [PMID: 3905822]
34. Teti A, Marchisio PC, Zallone AZ. Clear zone in osteoclast function: role of podosomes in regulation of bone-resorbing activity. Am J Physiol 1991; 261: C1-C7 [PMID: 1858848]
35. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273: 1236-1238 [PMID: 8703060]
36. Andersen TL, del Carmen Ovejero M, Kirkegaard T, Lenhard T, Foged NT, Delaissé JM. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone 2004; 35: 1107-1119 [PMID: 15542036]
37. Grigoriadis AE, Heersche JN, Aubin JE. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. J Cell Biol 1988; 106: 2139-2151 [PMID: 3384856]
38. Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999; 13: 1025-1036 [PMID: 10215629]
39. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342 [PMID: 12748652 DOI: 10.1038/nature01658nature01658]
40. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Löthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319 [PMID: 9108485]
41. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: A fatal attraction. Nat Rev Cancer 2011; 11: 411-425 [PMID: 21593787 DOI: 10.1038/nrc3055nrc3055]
42. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25: 4431-4437 [PMID: 17785705]
43. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139 [PMID: 21060033 DOI: 10.1200/JCO.2010.29.7101JCO.2010.29.7101]
44. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132 [PMID: 21343556 DOI: 10.1200/JCO.2010.31.3304JCO.2010.31.3304]
45. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007; 13: 387-403 [PMID: 17311556]
46. Nouh MA, Mohamed MM, El-Shinawi M, Shaalan MA, Cavallo-Medved D, Khaled HM, Sloane BF. Cathepsin B: A potential prognostic marker for inflammatory breast cancer. J Transl Med 2011; 9: 1 [PMID: 21199580 DOI: 10.1186/1479-5876-9-11479-5876-9-1]
47. Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 2012; 72: 1199-1209 [PMID: 22266111 DOI: 10.1158/0008-5472.CAN-11-27590008-5472.CAN-11-2759]
48. Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007; 67: 9894-9902 [PMID: 17942921]
49. Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, Wang H, Mehta A, Lombardi A. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 2010; 10: 452-458 [PMID: 21147688 DOI: 10.3816/CBC.2010.n.059S1526-8209(11)70193-8]
50. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005; 7: 485-496 [PMID: 15894268]
51. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massagué J, Kang Y. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009; 23: 1882-1894 [PMID: 19608765 DOI: 10.1101/gad.1824809gad.1824809]
52. Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res 2010; 70: 3494-3504 [PMID: 20406980 DOI: 10.1158/0008-5472.CAN-09-32510008-5472. CAN-09-3251]
53. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, Haffty BG, Pantel K, Massagu? J, Kang Y. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 2011; 20: 701-714 [PMID: 22137794 DOI: 10.1016/j.ccr.2011.11.002S1535-6108( 11)00408-9]
54. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10: 1165-1177 [PMID: 14502240 DOI: 10.1038/sj.cdd.44012854401285]
55. Hussein O, Tiedemann K, Murshed M, Komarova SV. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett 2012; 314: 176-184 [PMID: 22014409 DOI: 10.1016/j.canlet.2011.09. 026S0304-3835(11)00572-6]
56. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 2007; 176: 877-888 [PMID: 17353363]
57. Clézardin P. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 2011; 13: 207 [PMID: 21586099 DOI: 10.1186/bcr2835bcr2835]
58. Angelucci A. Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties. Curr Cancer Drug Targets 2009; 9: 1-18 [PMID: 19200048]
59. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502 [PMID: 16757721]
60. Pawlowski V, Révillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-Time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 4217-4225 [PMID: 11106235]
61. Burness ML, Grushko TA, Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 2010; 16: 23-32 [PMID: 20164687 DOI: 10.1097/PPO.0b013e3181d24fc1]
62. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmöller G, Pantel K. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 2001; 61: 1890-1895 [PMID: 11280743]
63. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmöller G. Differential expression of proliferation-Associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-1424 [PMID: 7688814]
64. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757 [PMID: 17512859]
65. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 2010; 21: 951-960 [PMID: 20813200 DOI: 10.1016/j.semcdb.2010.08.009S1084-9521(10)00146-1]
66. Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M, DAntonio A, De Filippi R, Pinto A. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 2005; 12: 471-482 [PMID: 15947117]
67. Qin L, Partridge NC. Stimulation of amphiregulin expression in osteoblastic cells by parathyroid hormone requires the protein kinase A and cAMP response element-binding protein signaling pathway. J Cell Biochem 2005; 96: 632-640 [PMID: 16088955 DOI: 10.1002/jcb.20550]
68. Gilmore JL, Scott JA, Bouizar Z, Robling A, Pitfield SE, Riese DJ, Foley J. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat 2008; 110: 493-505 [PMID: 17882547 DOI: 10.1007/s10549-007-9748-8]
69. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78 [PMID: 19573813 DOI: 10.1016/j.ccr.2009.05.0 17S1535-6108(09)00179-2]
70. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13: 513-609 [PMID: 9442882 DOI: 10.1146/annurev.cellbio.13.1.513]
71. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 2009; 283: 143-151 [PMID: 19398150 DOI: 10.1016/j.canlet.2009.03.035S 0304-3835(09)00227-4]
72. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67: 1580-1588 [PMID: 17308097]
73. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003; 63: 5028-5033 [PMID: 12941830]
74. Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, Susa M, Fabbro D, Bologna M, Teti A. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006; 318: 161-172 [PMID: 16627750]
75. Varricchio L, Migliaccio A, Castoria G, Yamaguchi H, de Falco A, Di Domenico M, Giovannelli P, Farrar W, Appella E, Auricchio F. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosinephosphorylated peptide. Mol Cancer Res 2007; 5: 1213-1221 [PMID: 18025264]
76. Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011; 17: 6897-6904 [PMID: 21903773 DOI: 10.1158/1078-0432.ccr-11-0070]
77. de Vries TJ, Mullender MG, van Duin MA, Semeins CM, James N, Green TP, Everts V, Klein-Nulend J. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 2009; 7: 476-488 [PMID: 19372577 DOI: 10.1158/1541-7786.MCR-08-02197/4/476]
78. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702 [PMID: 1997203]
79. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: Turning promise into triumph. Trends Pharmacol Sci 2012; 33: 122-128 [PMID: 22153719 DOI: 10.1016/j.tips.20 11.11.002S0165-6147(11)00208-2]
80. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011; 77: 1166-1171 [PMID: 21539969 DOI: 10.1016/j.urology.2011.01.006S0090-4295(11)00024-0]
81. Takahashi S, Miyazaki M, Okamoto I, Ito Y, Ueda K, Seriu T, Nakagawa K, Hatake K. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. Cancer Sci 2011; 102: 2058-2064 [PMID: 21781226 DOI: 10.1111/j.1349-7006.2011.02041.x]
82. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012; 118: 63-71 [PMID: 21976132 DOI: 10.1002/cncr.26204]
83. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-2931 [PMID: 20484021 DOI: 10.1158/1078-0432.CCR-09-23291078-0432. CCR-09-2329]
84. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002; 42: 469-499 [PMID: 11807180 DOI: 10.1146/annurev.pharmtox. 42.091901.11583842/1/469]
85. Möller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56 [PMID: 11242036 DOI: 10.1038/3506501635065016]
86. Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, Weigert R, Molinolo AA, Bouvier M, Gutkind JS. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal 2011; 4: ra60 [PMID: 21934106 DOI: 10.1126/scisignal.20022214/191/ra60]
87. Ueda Y, Neel NF, Schutyser E, Raman D, Richmond A. Deletion of the COOH-Terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-To-cell contact, enhanced motility and proliferation in breast carcinoma cells. Cancer Res 2006; 66: 5665-5675 [PMID: 16740704]
88. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z. Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by liganddependent degradation and HIF-1alpha. Biochem Biophys Res Commun 2006; 346: 252-258 [PMID: 16756955]
89. Huang YC, Hsiao YC, Chen YJ, Wei YY, Lai TH, Tang CH. Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. Biochem Pharmacol 2007; 74: 1702-1712 [PMID: 17904532]
90. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006; 25: 573-587 [PMID: 17165132 DOI: 10.1007/s10555-006-9019-x]
91. Tamamura H, Sugioka M, Odagaki Y, Omagari A, Kan Y, Oishi S, Nakashima H, Yamamoto N, Peiper SC, Hamanaka N, Otaka A, Fujii N. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg Med Chem Lett 2001; 11: 359-362 [PMID: 11212110 DOI: 10.1016/S0960-894X(00)00664-8]
92. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009; 21: 761-767 [PMID: 19212637]
93. Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, Story B, Zhao M, Mundy GR. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 2006; 66: 7548-7553 [PMID: 16885353]
94. Alexaki VI, Javelaud D, Van Kempen LC, Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS, Fournier PJ, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise TA, Mauviel A. GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst 2010; 102: 1148-1159 [PMID: 20660365 DOI: 10.1093/jnci/djq257djq257]
95. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005; 102: 1454-1459 [PMID: 15665096]
96. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008; 15: 621-627 [PMID: 18259201 DOI: 10.1038/cdd.2008.12cdd200812]
97. Harris AL. Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47 [PMID: 11902584 DOI: 10.1038/nrc704]
98. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679 [PMID: 15721472]
99. Voss MJ, Möller MF, Powe DG, Niggemann B, Zänker KS, Entschladen F. Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. BMC Cancer 2011; 11: 158 [PMID: 21535870 DOI: 10.1186/1471-2407-11-1581471-2407-11-158]
100. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93: 309-314 [PMID: 11181778]
101. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004; 23: 293-310 [PMID: 15197330 DOI: 10.1023/B:CANC.0000031768.89246. d75273266]
102. Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: An independent prognostic parameter? Breast Cancer Res 2004; 6: R191-R198 [PMID: 15084243 DOI: 10.1186/bcr775bcr775]
103. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph nodepositive breast cancer. Clin Cancer Res 2002; 8: 1831-1837 [PMID: 12060624]
104. Kovacic N, Croucher PI, McDonald MM. Signaling between tumor cells and the host bone marrow microenvironment. Calcif Tissue Int 2014; 94: 125-139 [PMID: 24046000 DOI: 10.1007/s00223-013-9794-7]
105. Owens P, Polikowsky H, Pickup MW, Gorska AE, Jovanovic B, Shaw AK, Novitskiy SV, Hong CC, Moses HL. Bone Morphogenetic Proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion. PLoS One 2013; 8: e67533 [PMID: 23840733 DOI: 10.1371/journal. pone.0067533PONE-D-13-03284]
106. Sceneay J, Smyth MJ, Möller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev 2013; 32: 449-464 [PMID: 23636348 DOI: 10.1007/s10555-013-9420-1]
107. Baker AM, Bird D, Welti JC, Gourlaouen M, Lang G, Murray GI, Reynolds AR, Cox TR, Erler JT. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res 2013; 73: 583-594 [PMID: 23188504 DOI: 10.1158/0008-5472.CAN-12-24470008-5472. CAN-12-2447]
108. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME, Semenza GL. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 2012; 90: 803-815 [PMID: 22231744 DOI: 10.1007/s00109-011-0855-y]
109. Tuncay OC, Ho D, Barker MK. Oxygen tension regulates osteoblast function. Am J Orthod Dentofacial Orthop 1994; 105: 457-463 [PMID: 8166095]
110. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007; 67: 4157-4163 [PMID: 17483326]
111. Frick KK, Bushinsky DA. Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclooxygenase-dependent mechanism. J Bone Miner Res 2003; 18: 1317-1325 [PMID: 12854843 DOI: 10.1359/jbmr.2003.18.7.1317]
112. Steinbrech DS, Mehrara BJ, Saadeh PB, Greenwald JA, Spector JA, Gittes GK, Longaker MT. VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. Am J Physiol Cell Physiol 2000; 278: C853-C860 [PMID: 10751333]
113. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009; 106: 2353-2358 [PMID: 19168635 DOI: 10.1073/pnas.08128011060812801106]
114. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105: 19579-19586 [PMID: 19020076 DOI: 10.1073/pnas. 08097631050809763105]
115. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002; 277: 29936-29944 [PMID: 12052835 DOI: 10.1074/jbc.M204733200M204733200]
116. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res 2011; 17: 5123-5131 [PMID: 21673063 DOI: 10.1158/1078-0432. CCR-11-06821078-0432.CCR-11-0682]
117. Mimeault M, Batra SK. Development of animal models underlining mechanistic connections between prostate inflammation and cancer. World J Clin Oncol 2013; 4: 4-13 [PMID: 23539141 DOI: 10.5306/wjco.v4.i1.4]
118. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009; 4: e6896 [PMID: 19727403 DOI: 10.1371/journal.pone.0006896]
119. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363-375 [PMID: 12726862]